Temozolomide chemotherapy in recurrent oligodendroglioma.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 11468326.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors determined the tolerance, response rate, and duration of recurrent anaplastic oligodendroglioma in 30 patients to temozolomide given orally at 150 to 200 mg/m2 on days 1 through 5 in cycles of 28 days. Nine patients responded: 7 of 27 patients (26%) treated with temozolomide after prior PCV chemotherapy and 2 of 3 chemotherapy-naive patients (both complete response). Median time to progression in responding patients was 13 months. Temozolomide shows promise and has an acceptable safety profile in recurrent anaplastic oligodendroglial tumors. Patients not responding to PCV may respond to temozolomide.
Medical subject headings
- Antineoplastic Agents
- Brain Neoplasms
- Dacarbazine
- Neoplasm Recurrence, Local
- Oligodendroglioma